Q3 EPS Estimates for Urogen Pharma Lifted by HC Wainwright

Key Points

• HC Wainwright raised its Q3 2027 EPS estimate for Urogen Pharma to $0.36 from $0.28 and maintained a Buy rating with a $75 price target. The broader analyst consensus is Moderate Buy, with an average target of $48.78.
• Urogen reported quarterly revenue of $72.46 million, exceeding the $63.55 million estimate, but its loss of $0.28 per share was slightly worse than the $0.26 consensus.
• Urogen shares opened at $45.60, near their 52-week high of $48.03, while institutional investors own 91.29% of the company and insiders have sold $892,661 of stock over the past three months.

Urogen Pharma (NASDAQ:URGN - Free Report) - Investment analysts at HC Wainwright upped their Q3 2027 earnings estimates for Urogen Pharma in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.36 per share for the quarter, up from their previous forecast of $0.28. HC Wainwright has a "Buy" rating and a $75.00 price objective on the stock. The consensus estimate for Urogen Pharma's current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Urogen Pharma's Q4 2027 earnings at $0.50 EPS.

Other research analysts have also issued research reports about the company. TD Cowen lifted their price target on Urogen Pharma from $50.00 to $60.00 and gave the stock a "buy" rating in a research report on Wednesday. Weiss Ratings reissued a "sell (d-)" rating on shares of Urogen Pharma in a report on Friday, July 17th. Guggenheim raised their target price on shares of Urogen Pharma from $42.00 to $58.00 and gave the stock a "buy" rating in a research report on Thursday. Oppenheimer lifted their target price on shares of Urogen Pharma from $40.00 to $50.00 and gave the company an "outperform" rating in a report on Thursday, July 16th. Finally, UBS Group reiterated a "buy" rating on shares of Urogen Pharma in a research report on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $48.78.

Urogen Pharma Stock Down 1.8%

Shares of NASDAQ URGN opened at $45.60 on Friday. The business has a 50-day moving average price of $36.07 and a 200 day moving average price of $26.98. The stock has a market cap of $2.22 billion, a PE ratio of -23.03 and a beta of 1.57. Urogen Pharma has a 52-week low of $15.86 and a 52-week high of $48.03.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02). The firm had revenue of $72.46 million during the quarter, compared to analyst estimates of $63.55 million.

Insider Activity at Urogen Pharma

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the company's stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the transaction, the insider owned 119,763 shares in the company, valued at approximately $4,790,520. This represents a 7.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 25,222 shares of company stock worth $892,661 in the last three months. 4.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Urogen Pharma

A number of large investors have recently made changes to their positions in the stock. Paradigm Biocapital Advisors LP purchased a new stake in shares of Urogen Pharma in the third quarter valued at about $84,111,000. Soleus Capital Management L.P. purchased a new position in shares of Urogen Pharma during the 2nd quarter worth approximately $29,934,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Urogen Pharma during the 4th quarter worth approximately $26,350,000. MPM Bioimpact LLC raised its position in shares of Urogen Pharma by 597.3% during the 4th quarter. MPM Bioimpact LLC now owns 941,378 shares of the company's stock worth $22,047,000 after purchasing an additional 806,378 shares during the last quarter. Finally, TCG Crossover Management LLC purchased a new stake in Urogen Pharma in the 3rd quarter valued at approximately $14,311,000. Hedge funds and other institutional investors own 91.29% of the company's stock.

Urogen Pharma News Summary

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: HC Wainwright raised its price target to $75 from $45 and reiterated a Buy rating. The new target implies approximately 64.5% upside from the referenced $45.60 price, signaling increased analyst confidence in Urogen’s commercial outlook. Benzinga The Fly
• Positive Sentiment: Second-quarter revenue was $72.46 million, above the $63.55 million analyst estimate. The company reported $50.4 million in ZUSDURI revenue, providing evidence of meaningful commercial traction and supporting the bullish analyst view. Urogen second-quarter financial results
• Neutral Sentiment: Management discussed the second-quarter results and company outlook during its earnings call, which investors may use to assess ZUSDURI’s sales trajectory, operating plans, and path toward profitability. Urogen Q2 2026 earnings call transcript
• Negative Sentiment: Urogen reported a quarterly loss of $0.28 per share, slightly worse than the $0.26 consensus estimate. Although the loss improved substantially from $1.05 per share a year earlier, continued losses and the EPS miss may be prompting profit-taking after the stock’s sharp run-up. Urogen earnings report

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra'anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company's lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source